-
Research findings presented at a February 2009 international conference indicate that an investigational gel known as PRO 2000 (Indevus Pharmaceuticals; Lexington, MA) proved about 30% effective in preventing HIV infection in women.
-
The next patient in your exam room is a 17-year-old female who uses the contraceptive injection depot medroxyprogesterone acetate (DMPA) for birth control.
-
Your next patient is an adolescent female who has requested immunization with the vaccine for human papillomavirus (HPV). When she asks specifically about the vaccine's safety, what can you tell her?
-
Rate control vs rhythm control for atrial fibrillation continues to be debated with most of the evidence falling on the side of rate control in recent years, primarily because of adverse effects from anti-arrhythmics. A new drug may change that however.
-
The FDA has issued a public health advisory regarding the risk of progressive multifocal leukoencephalopathy (PML) associated with use of efalizumab (Raptiva®) for the treatment of psoriasis.
-
-
Get used to the word "pharmacogenetics" — the discipline of studying genetic variation and its effect on responses to drugs.
-
The FDA is considering new tightened restrictions on use of opioid drugs. Manufacturers of these drugs will be required to have a Risk Evaluation and Mitigation Strategy to ensure that "the benefits of the drugs continue to outweigh the risks."
-
The first new urate-lowering drug has been approved in more than 40 years.
-
